Lite Strategy (LITS) Cash from Operations (2010 - 2026)
Lite Strategy (LITS) posted Cash from Operations of -$1.5 million for Q1 2026, up 21.2% on a QoQ basis from -$1.9 million in Q4 2025, and up 53.47% year-over-year from -$990394.9 in Q1 2025.
Analysis
Lite Strategy (LITS) Cash from Operations (2010 - 2026) Analysis & Trends
Lite Strategy has reported Cash from Operations for 17 years, with the latest figure at -$1.5 million in Q1 2026.
- On a quarterly basis, Cash from Operations rose 53.47% year-over-year to -$1.5 million in Q1 2026; TTM through Mar 2026 was -$10.4 million, a 71.36% increase from a year earlier, with the FY2025 full-year figure at -$20.8 million, up 58.7% from the prior year.
- Cash from Operations was -$1.5 million for Q1 2026 at Lite Strategy, up from -$1.9 million in the prior quarter.
- The five-year high for Cash from Operations was -$1.5 million in Q1 2026, with the low at -$18.5 million in Q3 2023.
- Average Cash from Operations over 5 years is -$9.7 million, with a median of -$11.3 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 91.45% in 2022, then jumped 86.33% in 2025.
- Over 5 years, Cash from Operations stood at -$14.3 million in 2022, then advanced by 22.53% to -$11.1 million in 2023, then jumped by 66.84% to -$3.7 million in 2024, then jumped by 47.38% to -$1.9 million in 2025, then grew by 21.2% to -$1.5 million in 2026.
- The last three Cash from Operations figures came in at -$1.5 million (Q1 2026), -$1.9 million (Q4 2025), and -$4.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -270.50 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | -1.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1.52 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Sep 30, 2025 | -4.51 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Sep 30, 2024 | -11.45 Mn |
| Jun 30, 2024 | -18.00 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -11.06 Mn |
| Sep 30, 2023 | -18.49 Mn |
| Jun 30, 2023 | -11.30 Mn |
| Mar 31, 2023 | -12.13 Mn |
| Dec 31, 2022 | -14.27 Mn |
| Sep 30, 2022 | -14.78 Mn |
| Jun 30, 2022 | -15.50 Mn |
| Mar 31, 2022 | -16.96 Mn |
| Dec 31, 2021 | -8.57 Mn |
| Sep 30, 2021 | -7.72 Mn |
| Jun 30, 2021 | -11.26 Mn |